These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8313205)

  • 1. Gonadotropin stimulation after pituitary desensitization with leuprolide acetate, comparison of FSH/hMG and hMG alone cycles--a study of 166 cases.
    Hwang FR; Chang MY; Soong YK
    Changgeng Yi Xue Za Zhi; 1993 Dec; 16(4):223-30. PubMed ID: 8313205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients.
    Benadiva CA; Davis O; Kligman I; Liu HC; Rosenwaks Z
    J Assist Reprod Genet; 1995 Jan; 12(1):8-12. PubMed ID: 7580013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
    Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
    J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of pure FSH alone or in combination for ovulation stimulation in in vitro fertilization.
    Acosta AA; Bernardus RE; Jones GE; Garcia J; Rosenwaks Z; Simonetti S; Veeck LL; Jones D
    Acta Eur Fertil; 1985; 16(2):81-99. PubMed ID: 3929523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function.
    Polan ML; Daniele A; Russell JB; DeCherney AH
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1284-91. PubMed ID: 3097055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles.
    Weghofer A; Munné S; Brannath W; Chen S; Barad D; Cohen J; Gleicher N
    Fertil Steril; 2009 Sep; 92(3):937-942. PubMed ID: 18774557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical significance of the ratio in FSH/LH of human menopausal gonadotropins in a programmed stimulation regimen for IVF-ET].
    Ikenaga H
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1223-9. PubMed ID: 8543846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled ovarian hyperstimulation for the new reproductive technologies.
    Navot D; Sandler B
    Acta Eur Fertil; 1989; 20(4):217-21. PubMed ID: 2519574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LH supplementation in mild stimulations cycles without pituitary suppression: a retrospective analysis.
    Paragona M; Rossini M; Dattilo M; Stamm J
    Gynecol Endocrinol; 2013 Feb; 29(2):101-4. PubMed ID: 23256611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization.
    Tsai HD; Chen CM; Lo HY; Chang CC
    Hum Reprod; 1995 Nov; 10(11):2909-12. PubMed ID: 8747042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.